AlloStim™ contains activated T-Stim™ cells formulated for infusion.

T-Stim™ cells are produced ex-vivo in a 9 day proprietary culture process (patents pending) in a bioreactor. T-Stim™ cells are produced from CD4+ CD45RA+ naïve T-cell precursors that are purified from the blood of normal donors.  Typically, 100 million of these cells can be purified from a normal donor. After the 9 days in culture approximately 10 billion T-Stim™ cells are produced.  There is no need to match the donor to the recipient as is required in BMT procedures.  The AlloStim™ product is an intentional mis-match to the recipient.

To generate T-Stim™ cells, the naïve CD4 cells are cultured on a matrix coated with monoclonal antibodies (mAbs).  These mAbs (anti-CD3 and anti-CD28) together with the cell-to cell contact due to the high density of the cells in culture causes the activation, expansion and maturation of the naïve CD4 cells.  The cells expand approximately 100-fold over the culture period resulting in one donor producing enough T-Stim™ cells for approximately 100 patients.

Under these controlled conditions, T-Stim™ cells mature into memory CD4 cells that produce extraordinary high amounts of IL-2, IFN-g and TNF-a upon activation.  Additionally, T-Stim™ cells express high density CD40L and FasL on the cell surface.  CD40L interacts with CD40 expressed on innate immune cells and activates these cells to produce Th1 cytokines and kill tumors. FasL enables these cells to directly kill tumors.

In order to produce the Mirror Effect™, the T-Stim™ cells require activation prior to infusion.  T-Stim™ cells are activated with monoclonal antibody-coated particles that are removed prior to infusion.  When T-Stim™ cells are activated and formulated the product is called “AlloStim™”.

To see how the AlloStim™ product works, please click on the button below: